Unknown

Dataset Information

0

Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.


ABSTRACT: We have previously reported that a subunit protein vaccine based on the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing Ab responses in immunized animals. In this study, systemic, mucosal, and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, with comparison of the i.m. and intranasal (i.n.) routes of administration. Our results demonstrated that: 1) the i.n. vaccination induced a systemic humoral immune response of comparable strength and shorter duration than the i.m. vaccination, but the local humoral immune response was much stronger; 2) the i.n. vaccination elicited stronger systemic and local specific cytotoxic T cell responses than the i.m. vaccination, as evidenced by higher prevalence of IL-2 and/or IFN-gamma-producing CD3+/CD8+ T cells in both lungs and spleen; 3) the i.n. vaccination induced similar protection as the i.m. vaccination against SARS-CoV challenge in mice; 4) higher titers of mucosal IgA and serum-neutralizing Ab were associated with lower viral load and less pulmonary pathological damage, while no Ab-mediated disease enhancement effect was observed; and 5) the vaccination could provide long-term protection against SARS-CoV infection. Taken together, our findings suggest that RBD-rAAV can be further developed into a vaccine candidate for prevention of SARS and that i.n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile.

SUBMITTER: Du L 

PROVIDER: S-EPMC2603051 | biostudies-literature | 2008 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.

Du Lanying L   Zhao Guangyu G   Lin Yongping Y   Sui Hongyan H   Chan Chris C   Ma Selene S   He Yuxian Y   Jiang Shibo S   Wu Changyou C   Yuen Kwok-Yung KY   Jin Dong-Yan DY   Zhou Yusen Y   Zheng Bo-Jian BJ  

Journal of immunology (Baltimore, Md. : 1950) 20080101 2


We have previously reported that a subunit protein vaccine based on the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein and a recombinant adeno-associated virus (rAAV)-based RBD (RBD-rAAV) vaccine could induce highly potent neutralizing Ab responses in immunized animals. In this study, systemic, mucosal, and cellular immune responses and long-term protective immunity induced by RBD-rAAV were further characterized in a BALB/c mouse model, wi  ...[more]

Similar Datasets

| S-EPMC7745033 | biostudies-literature
| S-EPMC8146944 | biostudies-literature
| EMPIAR-10947 | biostudies-other
| S-EPMC8388188 | biostudies-literature
2021-02-02 | GSE155536 | GEO
2024-02-14 | GSE245040 | GEO
| S-EPMC9240059 | biostudies-literature
| S-EPMC9270963 | biostudies-literature
| EMPIAR-10891 | biostudies-other